SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the ...

SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...

Researchers led by the Institute of Molecular and Clinical Ophthalmology Basel uncovered disease-causing variants in ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.

A new research paper featured as the cover of Volume 17, Issue 12 of Aging-US was published on December 22, 2025, titled "A ...

IOB researchers, in collaboration with a team from Radboud University Medical Center and partners from more than 100 institutions worldwide, identify new genetic cause of inherited blindness. The ...

A new research paper featured as the cover of Volume 17, Issue 12 of Aging-US was published on December 22, 2025, titled “A ...